Telix Pharmaceuticals stock drops as markets digest a $2.35 billion merger with Isotope Technologies Munich, overshadowing analyst optimism for the radiopharmaceutical firm.
Telix announced a $2.35 billion merger with ITM, and its stock crashed despite analyst optimism.
Telix Pharmaceuticals shares tumbled on Monday after the Melbourne-based radiopharmaceutical developer announced a $2.35 billion merger with Germany's ITM. Despite positive sentiment from analysts regarding the strategic move, investors reacted negatively to the acquisition terms.
The stock declined following the announcement of a $2.35 billion merger with ITM, as market participants reacted negatively to the deal despite analyst optimism.